Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
Karin Ribi, Weixiu Luo, Marco Colleoni, Per Karlsson, Jacquie Chirgwin, Stefan Aebi, Guy Jerusalem, Patrick Neven, Vincenzo Di Lauro, Henry L. Gomez, Thomas Ruhstaller, Ehtesham Abdi, Laura Biganzoli, Bettina Müller, Annelore Barbeaux, Marie-Pascale Graas, Manuela Rabaglio, Prudence A. Francis, Theodoros Foukakis, Olivia Pagani, Claudio Graiff, Daniel Vorobiof, Rudolf Maibach, Angelo Di Leo, Richard D. Gelber, Aron Goldhirsch, Alan S. Coates, Meredith M. Regan & Jürg Bernhard on behalf of the SOLE Investigators
Manuscript
British Journal of Cancer
2019
PROVA
